Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 08 - 10 entities : Crinetics pharmaceuticals, inc. save search
Crinetics Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update
Published: 2021-08-10 (Crawled : 22:00) - biospace.com/
CRNX G | $43.72 -1.13% 100K
|
Health Technology
|
| O: -0.06%
H: 5.87%
C: 4.33%
financial results results
Crinetics Pharmaceuticals’ Oral ACTH Antagonist, CRN04894, Demonstrates Pharmacologic Proof-of-Concept with Dose-Dependent Cortisol Suppression in Single Ascending Dose Portion of Phase 1 Study
Published: 2021-08-10 (Crawled : 22:00) - biospace.com/
CRNX G | $43.72 -1.13% 100K
|
Health Technology
|
| O: -0.06%
H: 5.87%
C: 4.33%
phase 1
CRN04894, Demonstrates Pharmacologic Proof-of-Concept with Strong Dose-Dependent Cortisol Suppression in Phase 1 Single Ascending Dose Study
Published: 2021-08-10 (Crawled : 21:00) - crinetics.com
CRNX G | $43.72 -1.13% 100K
|
Health Technology
|
| O: 10.0%
H: 6.56%
C: -1.24%
phase 1 phase 2 phase 3
Crinetics’ Second Quarter 2021 Financial Results and Corporate Update
Published: 2021-08-10 (Crawled : 21:00) - crinetics.com
CRNX G | $43.72 -1.13% 100K
|
Health Technology
|
| O: 10.0%
H: 6.56%
C: -1.24%
financial results results
Crinetics Reviews CRN04894 Single-Ascending Dose Results
Published: 2021-08-10 (Crawled : 21:00) - crinetics.com
CRNX G | $43.72 -1.13% 100K
|
Health Technology
|
| O: 10.0%
H: 6.56%
C: -1.24%
results
Gainers vs Losers
| 55% | 45% |
Top 10 Gainers
CSSE 4 | $0.3499 129.74% 150M
|
Consumer Services
CZOO | $11.04 121.24% 9.6M
|
BOF | $1.88 60.68% 98M
|
AMST | $3.2 60.0% 63M
|
Technology Services
LICN | $0.8592 53.43% 13M
|
WIMI | $1.03 41.99% 15M
|
Technology Services
MULN | News | $3.675 34.62% 11M
|
Information
RILY | $28.605 31.7% 9.9M
|
Finance
RBBN 4 | $3.305 28.6% 1.9M
|
Electronic Technology
RCAT | $1.53 27.5% 2.9M
|
Information
Your saved searches
Save your searches and get alerts when important news are released.